Health Trials

PNH - Paroxysmal Nocturnal Hemoglobinuria

3

Review clinical trials related to PNH - Paroxysmal Nocturnal Hemoglobinuria. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Lanyi Therapeutics Co., Ltd.Updated: May 14, 2026Locations: 2
Eligibility criteria

Male or female subjects aged ≥18 years. [+13]

History of allogeneic bone marrow transplantation. [+20]

Read more
Status: Recruiting

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally

Participants needed: 24
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: S-INFINITY Pharmaceuticals Co., LtdUpdated: May 18, 2025Locations: 1
Eligibility criteria

Male or female with aged ≥18 years old; [+6]

Subjects with laboratory evidence of bone marrow failure during the screening pe... [+6]

Read more
Status: Not yet recruiting

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The proposed study, NM8074-PNH-101, is a phase II, open-label, multi-dose, unicenter trial to evaluate the safety and efficacy of NM8074 in Soliris-treated PNH subjects.

Participants needed: 6
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: NovelMed TherapeuticsUpdated: Mar 30, 2025
Eligibility criteria

Male or female patients ≥ 18 years at the time of consent [+7]

Platelet count < 30,000/µL at Screening [+19]

Read more